Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsDalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewDalbavancin: a novel antimicrobialNew developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancinDalbavancin for the treatment of acute bacterial skin and skin structure infectionsNewer antibacterial drugs for a new century.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensLinezolid for the treatment of drug-resistant infections.Current and novel antibiotics against resistant Gram-positive bacteriaComparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesFactors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.Dalbavancin: a new option for the treatment of gram-positive infections.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Review of dalbavancin, a novel semisynthetic lipoglycopeptide.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.Emergence and management of drug-resistant enterococcal infections.Vancomycin resistance: are there better glycopeptides coming?A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolatesDalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Targeting a cell wall biosynthesis hot spot.Bactericidal activity and resistance development profiling of dalbavancin.Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
P2860
Q24646677-84F67AC7-2380-4E70-9536-B5806F382E17Q24647429-16E8449E-965B-407D-A612-9715643710C9Q24674841-BC19D2F8-A99E-40C3-8B58-CBD5916319F6Q26764885-5545FA58-0E6F-4C86-870A-F7A9F4EC6F85Q26799598-E76A4C89-ABD8-4C1E-A751-CF5910EEB977Q30433333-DAD7F2F7-44D6-41EA-80DE-2E342BB4D096Q33788308-52EC719E-8E5D-4F65-B3A3-51A046826BF2Q34894133-15C70ECB-0DF6-4531-AB32-65C016912FB0Q35026521-9778A114-D38B-4394-B5EF-9BC79A2A0617Q35073036-1421ACDB-8D47-4190-B545-F80A691CB324Q35690571-321EFFD1-4906-4B85-8D1A-3AAB19A5A342Q36098775-853EFD2B-BAF6-4B8F-BF8A-DB17B77A3A06Q36409507-5BAF7253-C90D-4519-9B8E-C912A5AEE954Q36758570-F77DB6F0-486B-4BE1-8C92-E1D18BE3D0ADQ36802632-C20D4685-E555-4541-BD32-2F215572796DQ36901937-3887A81C-0185-4308-9AD1-4BFBBE4C7341Q37291346-738DD0FB-8087-456C-9754-37442EC676FEQ37340562-08B135CF-82AA-42B7-96AC-D76FF3888F12Q37661510-4565DCF7-A48D-474A-814E-F148FAA691B7Q37809666-32599CA1-8AF3-4331-BF7F-B33D9653DC0EQ38314386-8F1536DE-83AF-47A0-AF6A-DA05B2A82F27Q38646905-7014DBEE-5C5A-44E4-A54C-5CDA8A06FAEDQ39413308-4B7DB713-3632-42CE-92B3-1D449010F5F9Q41839607-7F10D2D6-F7DD-4CF9-A8A1-BE41B473F47FQ41958813-D2B8D59D-FEBE-4998-9CEA-426E6BFB8DA7Q43066197-27B0D288-8EEC-4621-8630-3DB43790F57CQ46274310-2C0912FD-4638-4CDC-9CD6-64C528F1FF29
P2860
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@en
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@nl
type
label
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@en
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@nl
prefLabel
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@en
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@nl
P2093
P1476
Dalbavancin activity against s ...... stant Gram-positive pathogens.
@en
P2093
Jennifer M Streit
Ronald N Jones
Thomas R Fritsche
P304
P356
10.1016/J.DIAGMICROBIO.2005.03.004
P577
2005-12-01T00:00:00Z